Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by stock analysts at Leerink Swann in a report issued on Wednesday. They presently have a $530.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s price objective would suggest a potential upside of 30.46% from the stock’s previous close.

A number of other research firms have also commented on REGN. Vetr raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 price target for the company in a report on Tuesday, August 2nd. Canaccord Genuity reaffirmed a “hold” rating and issued a $450.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Robert W. Baird lowered Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $505.00 to $448.00 in a report on Friday, August 5th. Cowen and Company reaffirmed a “hold” rating and issued a $430.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $471.78.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.28% during trading on Wednesday, hitting $401.05. The stock had a trading volume of 211,934 shares. The company has a 50-day moving average of $408.70 and a 200-day moving average of $389.50. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The stock has a market capitalization of $41.96 billion, a P/E ratio of 62.57 and a beta of 1.24.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/regeneron-pharmaceuticals-inc-regn-given-buy-rating-at-leerink-swann.html

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The business earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the business posted $2.89 earnings per share. The business’s revenue for the quarter was up 21.4% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post $10.93 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the transaction, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.40% of the company’s stock.

Hedge funds have recently modified their holdings of the company. IFP Advisors Inc boosted its stake in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $140,000. Brave Asset Management Inc bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $157,000. Finally, Bessemer Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares in the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.